UNSPSC 51361941: Vinbarbital sodium

This classification denotes a barbiturate with the molecular formula C11H15N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BAS6234GZ7, chemically known as sodium 5-ethyl-5-(1-methyl-1-butenyl)barbiturate, but more generally known as vinbarbital sodium, which bears US NIH Compound Identifier 5284636. European Medicines Agency schedules vinbarbital sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00051MIG.

Most nations, for tariff purposes, schedule vinbarbital sodium under HS 29335400. Vinbarbital sodium bears US NLM identifiers UMLS ID C2700248 and NCI Concept Code C77632. SMILES: CC/C=C(\C)/C1(C(=O)NC(=O)[N-]C1=O)CC.[NA+].

UNSPSC 51361941 Vinbarbital sodium is a Commodity code representing individual pharmaceutical products procured by state and local health agencies, though recent posted opportunities show minimal direct activity under this specific code. The solicitations currently tagged to this code diverge significantly from the code's nominal scope—state and local governments are instead actively procuring broader pharmaceutical categories including naloxone, generic multi-source drugs, and over-the-counter products through cooperative purchasing mechanisms and direct procurement channels. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). These entities conduct procurements through RFPs, RFQs, and competitive bidding processes to support community health initiatives, pharmacy benefit programs, and facility operations across multiple states and local jurisdictions.

Recent activity spans Florida, Texas, and Minnesota through MMCAP's multi-state network. Seminole County issued IFB 60459723LAS in June 2026, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to its community health building and a response deadline of July 26, 2023. Texas HHS issued RFI HHS0017013 in April 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling the state's intent to develop direct contracting relationships outside traditional pharmacy benefit manager arrangements. MMCAP posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, requiring compliance with cGMP and Drug Supply Chain Security Act standards, with proposals due March 26, 2026 and contracts effective July 1, 2026. Vendors participating in MMCAP must work through three authorized wholesalers and maintain commercial general liability insurance of $5,000,000 per occurrence.